Seeking Alpha

Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for...

Regeneron (REGN) -4.1%, although it's not obvious why. Q4 sales of Eylea, its eye treatment for wet age-related macular degeneration, were $276M. That's above estimates of $264.2M and brings the total for 2012 to $838M. Regeneron forecasts that U.S. sales will grow 50%, leading to annual revenue of $1.26B and already beating a Citigroup prediction that Eylea would generate peak annual sales of $1.1B in 2021. (Presentation for JPM conference)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs